« Return to News | Awards & Advancement

Akesis names John L. Capicchioni as new president

Thursday, May 31, 2012 12:34 PM

Akesis, a Lake Wylie, S.C.-based contract research firm specializing in phase II-IV clinical dermatology services and regulatory affairs consulting, has appointed John L. Capicchioni as its new president.

Capicchioni will be responsible for providing strategic leadership and managerial oversight of the company while driving growth and assuring quality, cost optimization and best business practices to pharmaceutical, device, generic, formulation development and biotechnology companies.

Capicchioni brings 22 years of global CRO experience to Akesis. He has held a broad range of executive leadership positions, overseeing global sales, project management, marketing and client services. He has served as senior vice president of business development for global early clinical and bioanalytical research at MDS Pharma Services (now Celerion), where he directed the pharmaceutical and generic segments. He has also held senior posts at Phoenix International Life Sciences. Capicchioni has also served on the board of directors of the Generic Pharmaceutical Association as the elected member for CROs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.